General Information of Drug (ID: DM1B3UM)

Drug Name
GDC-0152 Drug Info
Synonyms GDC 0152; GDC0152
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [2]
Cross-matching ID
PubChem CID
46940575
CAS Number
CAS 873652-48-3
TTD Drug ID
DM1B3UM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT-406 DMVJW0S Squamous head and neck cell carcinom 2D60.0 Phase 3 [3]
Birinapant DM6PBUM Lymphoma 2A80-2A86 Phase 2 [4]
Phenoxodiol DMBUJVX Ovarian cancer 2C73 Phase 1/2 [5]
APG-1387 DMLEKUY Haematological malignancy 2B33.Y Phase 1 [6]
HGS-1029 DMS9WXG Haematological malignancy 2B33.Y Phase 1 [7]
PMID25980951-Compound-6 DMVSW5N N. A. N. A. Patented [8]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [8]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [8]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [8]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
X-linked inhibitor of apoptosis protein (XIAP) TTR7B60 XIAP_HUMAN Modulator [1]

References

1 Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
2 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3 Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
4 cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
7 Clinical pipeline report, company report or official report of Aegera Therapeutics Inc.
8 Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.